A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Belimumab (Primary) ; Azathioprine; Cyclophosphamide; Mycophenolate; Steroids
  • Indications Lupus nephritis
  • Focus Therapeutic Use
  • Acronyms BLISS-LN
  • Sponsors GlaxoSmithKline; Human Genome Sciences
  • Most Recent Events

    • 26 Jan 2017 Planned End Date changed from 1 Sep 2019 to 1 Feb 2020.
    • 26 Jan 2017 Planned primary completion date changed from 1 Feb 2019 to 1 Jul 2019.
    • 05 Jul 2016 Planned End Date changed from 1 Mar 2019 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top